Beyond the Scale: The Ozempic Effect

What did Meta and YouTube know about the harm they were causing to children — and when did they know it? The evidence just went before a jury for the first time, and the verdict is in. In this episode, attorney and consumer safety advocate Whitney Di Bona sits down with Nicki Petrossi, host of the Scrolling 2 Death podcast and former social media marketing executive, who spent nearly every day ins...

Discover the alarming evidence linking glyphosate, the world's most widely used herbicide, to serious health risks, including cancer. Join attorney Whitney Di Bona and Kelly Ryerson, also known as the Glyphosate Girl, as they unpack the ongoing courtroom battles, regulatory failures and urgent need for reform in our food system.  To learn more about Roundup lawsuits, visit https://www.drugwatch.co...

In the final episode of Big Pharma Behind the Scenes, Drugwatch Investigates explores what it would take to fix the system. Hosts Terry Turner and attorney Whitney Ray Di Bona dig into the Depo-Provera meningioma warning, FDA funding, and industry influence over regulation. Plus, they ask the bigger question at the heart of the series: Can regulators keep up, or will patients always have to rely o...

In this episode, we go inside some of the biggest drug and device mass torts in U.S. history. Terry Turner and Whitney Ray Di Bona explore how multidistrict litigations (MDLs) — some involving tens of thousands of lawsuits — helped expose hidden risks, uncover internal company documents and drive record settlements in cases involving Roundup, Vioxx, talc, mesh and more. You can read more about Big...

This episode of Big Pharma Behind the Scenes looks at the price of corporate misconduct and the billion-dollar settlements that keep repeating. Terry Turner and Whitney Ray Di Bona break down why companies like Pfizer, GSK, Johnson & Johnson and others keep showing up in enforcement actions — and whether fines, lawsuits and whistleblowers actually change behavior or just become the cost of doi...

Drugwatch Investigates follows the money behind blockbuster drugs and toxic products to uncover a bigger pattern of socialized risk and privatized profit.  The episode looks at how slow regulation, aggressive marketing, thin approval evidence and delayed transparency can leave patients, taxpayers and insurers paying the price while companies keep selling and fighting in court. Hosts Terry Turner a...

Hosts Terry Turner and Whitney Ray Di Bona unpack how companies plan for legal risk long before products reach patients — from trial design and FDA strategy to marketing, lobbying and bankruptcy maneuvers like Johnson & Johnson’s failed “Texas Two-Step” talc strategy.  The episode features investigative reporters Shannon Brownlee and Jeanne Lenzer on how drugmakers shape the evidence behind ap...

Drugwatch reveals how the legal system steps in when drug safety fails. Hosts Terry Turner and Whitney Ray Di Bona investigate new lawsuits over rare, permanent vision loss tied to GLP‑1 drugs like Ozempic and Wegovy. This discovery uncovers a wider trend — drugs approved on limited evidence, safety risks surfacing only after millions of prescriptions and families seeking answers in court.  Stanfo...

In this special bonus episode, hosts Terry Turner and Christian Simmons revisit the topic of GLP-1 drugs to dive into emerging health concerns for Saxenda and Victoza. New research has uncovered a potential link between liraglutide, the active ingredient in those drugs, and permanent vision loss. To better understand the impact of this issue, Terry and Christian once again speak with attorney Dani...

GLP-1 drugs like Ozempic and Wegovy have reshaped how we treat obesity and diabetes — but what’s on the horizon? In this final episode of Beyond the Scale: The Ozempic Effect , hosts Terry Turner and Christian Simmons explore the future of these groundbreaking medications through insights from top experts.  Dr. William Hsu discusses the possibility of diabetes remission without lifelong medication...

In this revealing episode, hosts Terry Turner and Christian Simmons dive into the side effects and emerging lawsuits surrounding popular GLP-1 drugs like Ozempic, Wegovy and Mounjaro. Clinical pharmacist Dr. Lauren Cunningham breaks down how these medications work, their common side effects and when patients should be cautious. Health coach and former pharmacist Dr. Ashley Dwyer shares practical a...

In Episode 4 of Beyond the Scale: The Ozempic Effect , hosts Terry Turner and Christian Simmons investigate the growing off-label use of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro — especially among people without diabetes.  As demand surges, so does the use of cheaper, unregulated compounded versions sold through telehealth and med spas. Metabolic health expert Dr. Matt Chalmers explains who...

In this episode of Beyond the Scale: The Ozempic Effect , hosts Terry Turner and Christian Simmons explore the high cost of GLP-1 medications like Ozempic and Wegovy — and why many Americans still can’t afford them.  Former Congressman Robert Andrews, a key architect of the Affordable Care Act and now CEO of the Health Transformation Alliance, explains why these medications remain so expensive and...

In this episode of Beyond the Scale: The Ozempic Effect , hosts Terry Turner and Christian Simmons break down how GLP-1 drugs like Ozempic, Wegovy and Mounjaro work inside the body. These medications do more than suppress appetite — they change digestion, regulate blood sugar and even influence fat metabolism.  Clinical pharmacist Dr. Elizabeth Van Dril explains why these drugs are considered a br...

Where did drugs like Ozempic, Wegovy and Mounjaro come from? In this premiere episode of Beyond the Scale: The Ozempic Effect , hosts Terry Turner and Christian Simmons trace the surprising origins of GLP-1 medications — from a hormone found in Gila monster venom to one of the most talked-about drug classes in the world.  Joined by clinical pharmacists Dr. Lauren Cunningham and Dr. Elizabeth Van D...